KRIBIOLISA Neutralizing Antibodies to Evolocumab (REPATHA) ELISA includes features like:
– Ready to use protocol with break-apart wells for ease of use
– Standardisation and High Reproducibility
– Lot to Lot Consistency
– Accuracy and Precision
Validated against seven points for a ?GOLD RING? Standard Quality ELISA – the benchmark sign for Krishgen Quality. KRIBIOLISA ELISA kit is used for assessing the specific biomarker in samples analytes which may be human serum, plasma, biological fluids and cell culture supernatant. The kit uses indirect sandwich assay with double antibodies / recombinant proteins – capture and detection to ensure a high degree of sensitivity and specificity in the estimation of the analyte. Extensive validation has been done on these kits. Please ask for our validation guide if not availableon our product page. Incase you wish us to customize the kit, connect with us at sales1@krishgen.com
Background: The KRIBIOLISA? ELISA kits are used for assessing the specific biomarker in samples analytes which may be serum and cell culture supernatant as validated with the kit. The kit employs a blocking ELISA technique which engages the blocking pathway to estimate the neutralizing antibodies. Evolocumab is a PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor antibody used as an adjunct to LDL cholesterol reducing therapies, aiding in the prevention of cardiovascular events and cardiovascular revascularization procedures. A neutralizing antibody (NAb) is an antibody that is responsible for defending cells from pathogens and are produced naturally by the body as part of its immune response. Their production is triggered by both infections and vaccinations against infections. In an immunogenetic context it will bind to a drug and neutralize its therapeutic effect. Intended Use: The KRIBIOLISA? Neutralizing Antibodies to Evolocumab (Repatha) ELISA kit is used as an analytical tool for the qualitative detection of neutralizing antibodies against Evolocumab in serum or plasma. Principle: The method employs sandwich ELISA technique. The protein-protein interaction between HRP-Evolocumab and PCSK9 can be blocked by Evolocumab. The neutralizing antibodies against Evolocumab binds to Evolocumab and thus a competitive inhibition is created. Samples and controls are pipetted in a blank microtitre plate and incubated with neutralizing antibody to Evolocumab (NAb) and Evolocumab. This complex of bound and unbound Evolocumab is then incubated with HRP conjugated Evolocumab protein. The unbound Evolocumab will bind to the PCSK9. The bound Nab Evolocumab will not bind to the HRP conjugated Evolocumab. This complex solution of bound antibodies to Evolocumab and unbound Evolocumab is then pipetted into PCSK9 coated microplate. After washing, the substrate solution (TMB) is added to the microwells. Post incubation, color develops proportionate to the amount of bound Evolocumab. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!View more details about our Publication Reward